News >

FDA Approval Sought for Belantamab Mafodotin in Relapsed/Refractory Myeloma

Jason M. Broderick @jasoncology
Published: Tuesday, Dec 17, 2019

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute

Sagar Lonial, MD, FACP

A biologics license application (BLA) has been filed with the FDA for belantamab mafodotin (GSK2857916) for the treatment of patients with relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory drug (IMiD), a proteasome inhibitor (PI), and an anti-CD38 antibody, according to GlaxoSmithKline (GSK), the manufacturer of the BCMA-targeting antibody-drug conjugate (ADC).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x